Rough Draft Atlanta on MSN22h
Researchers expect FDA to approve a twice-yearly shot that reduces risk of HIV infection by 96%Roughly 61,000 Georgians live with HIV, the sexually transmitted virus (STI) that can lead to AIDS, and Atlanta ranks in the ...
The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...
WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...
Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...
The 2024 breakthrough of the year, according to the journal Science, was with the drug lenacapavir, an antiretroviral medicine that performed very well in scientific trials. Dr. Robert Hopkins Jr ...
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
The post appears to reference the drug lenacapavir, which reportedly can cost around $40,000 annually in the U.S. and is administered in twice-yearly doses. While the drug appears to be effective ...
Uganda is registering around 38,000 new infections despite the deployment of different interventions such as condoms and oral ...
In light of the recently announced plan to put 2.5 million people on injectable pre-exposure prophylaxis (PrEP), specifically lenacapavir, by 2027, AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback